What’s Next For CatSci In 2022

Jan 14th 2022
What’s Next For CatSci In 2022

Year on year, CatSci continues to evolve; we are experts, we are innovative, and we are committed. We are incredibly proud of the unparalleled strategic value we add to each one of our customers’ projects to meet the healthcare needs of the world.

It’s a New Year, and we are ready for another year of excellence. We would like to share just a snippet of what 2022 holds for CatSci. As always, we continue our mission of offering more and better to our customers, so that they can deliver best-in-class therapeutics to those in need.

Growing Team

At the very beginning of this year, we were thrilled to welcome our new Director of Pharmaceutical Development, Dr Gary Parsons, who will be bringing his breadth of knowledge and experience to the team. Gary completed his PhD at the University of London on the the stability of nonaqueous nonpolar suspensions, and has worked in the pharmaceutical industry ever since. He worked initially in formulation development roles, gaining experience across multiple types of medicine and drug substances, including small molecules, proteins and RNA-based therapeutics. He has held a number of Senior Director roles, including the global leadership of early-phase developability and product design departments focusing on acceleration to clinical studies. He has particular expertise in inhaled product development and has worked across all phases of development, from lead optimisation to initial commercial supply in support of the creation of GSK’s Ellipta portfolio of Inhaled medicines.

Dr. Parsons will be influential in building out our integrated capability from particle to product, enabling us to advance more therapeutics to launch.

More and Better Capabilities

We are extremely excited to announce that 2022 will see the delivery of GMP capability at our Dagenham facility. This key milestone will further increase our ability to provide innovative, tailored solutions, from early development pre-clinical data packages to late development Phase III impurity fate studies.

We are also pleased to announce that we will build an in-house oligonucleotide capability at our Dagenham site, from both an analytical and synthetic perspective. This will support the use of oligonucleotides in wider drug discovery and development programmes, and will continue to facilitate our mission of becoming a fully integrated CMC innovation partner.

2022 will also see the continued improvement in our material supply capability. We aim to break down silos between drug substance and drug product development and, ultimately, enhance the probability of small molecule success.

Enhanced Facilities

This year, we will be opening a further two process development laboratories and another new analytical laboratory at our Cardiff site, as well as upgrading our existing labs, too. The increased capacity will ensure that we always match, and even surpass, our customers’ internal capabilities and allow us to continually offer more and better.

We will be further cementing our collaboration with Shimadzu at our site. Through this partnership, we will continue to power the delivery of tailored analytical solutions with state-of-the-art equipment and engineering.

In 2021, we solidified strategic partnerships with expert companies, including the Cambridge Crystallographic Data Centre (CCDC), New Path Molecular Research, and Argonaute RNA. We will continue to build on these relationships in 2022; this is a reflection of our commitment to always enhancing our capabilities and expanding our offering to better help our customers.

Green Chemistry

Since CatSci’s beginning, we have been passionate about developing innovative, green, and cost-effective manufacturing processes for small molecule therapeutics. We are always reviewing our processes and looking for ways we can be more sustainable. We use 100% carbon-free energy sources and, this year, we are significantly investing in a new electricity substation at our site to enable us to provide green power for the electrical heating system.

Furthermore, we have an exciting green competition coming up that will encourage all our employees to be as eco-conscious as possible.

Virtual Poster Competition

At CatSci, we are passionate about the scientists of tomorrow. This is why we are hosting a Virtual Poster Competition on Wednesday 15th February 2022. The CatSci Award will be presented to the winning presentation, which is a cash prize of £1000 and the opportunity to present at a future CatSci symposium. This is an excellent opportunity to highlight the emerging talent in the field, and allow final year PhD students to demonstrate their research.

Submissions for entry are now closed, but the free event is open to the public to join! Attendees will be able to network with the chemistry community in our virtual LinkUp room on LabLinks, as well as vote for their favourite posters. Spaces are limited, so be sure to reserve your spot now by heading here.

Early Careers Scheme

As part of our dedication to the future of young scientists, 2022 will also see the return of our graduate scheme, which is even bigger and better than this year’s! We are passionate about the future of drug development; this programme is for MChem graduates with a passion for creating best-in-class therapeutics in a green and cost-effective way looking to begin their career whilst focusing on personal development. If this sounds like the perfect role for you, then make sure you apply now.

CatSci Virtual Open Day

We will also be hosting an online open day on Wednesday 2nd February 2022. This will be an opportunity for students and graduates to find out what a career at CatSci is like, talk to our scientists and find out all about our upcoming job roles. You can reserve your space here.

Discover More About CatSci

CatSci opens new Dagenham laboratory dedicated to analytical excellence

CatSci CEO Ross Burn Included on The Medicine Maker’s 2021 Power List